Press release
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
Low-Grade Serous Ovarian Cancer (LGSOC) is a Unique and Distinct Ovarian Cancer, Requiring Tailored Resources and Management Approach for Patients Initiative
About this update from Verastem, Inc.
[{"type":"text","content":"\nLow-Grade Serous Ovarian Cancer (LGSOC) is a Unique and Distinct Ovarian Cancer, Requiring Tailored Resources and Management Approach for Patients\n\nInitiative Developed with Input from Patients, Advocates and Physicians Provides Information and Support\n\n BOSTON--(BUSINESS WIRE)--\nVerastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of Let’s Talk About LGSOC, a new initiative that calls attention to low-grade serous ovarian cancer (LGSOC). Let’s Talk About LGSOC provides detailed information about LGSOC and its symptoms, its differences from the more common high-grade serous ovarian cancer (HGSOC), tips and resources, and ways to connect with others in the LGSOC community.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005022/en/(Graphic: Business Wire)\nLGSOC is a rare form of ovarian cancer that commonly affects younger women with a median age at diagnosis between 45-551, and for many, the disease and its treatment will have a long-lasting impact on mental and physical health, including fertility and early menopause.2,3,4 Limited treatment options are available for LGSOC and no treatments specifically for LGSOC have been approved to date.5\n\n“When I was diagnosed with LGSOC, it would have been immensely helpful to have specific information and discussion about the disease that I could relate to,” said Tiffany Stout, who was diagnosed in her 30s and has been living with LGSOC for eight years. “At the time, I felt I had to do a lot of research on my own to better understand my diagnosis, how LGSOC was different, and what it would mean for my future. Let’s Talk About LGSOC tackles the need for disease awareness and fosters connection amongst those living with LGSOC and with the advocacy organizations that are there to support us.”\n\nLGSOC has only recently been classified as a separate disease as compared to the more common high grade serous ovarian cancer (HGSOC) with different epidemiology, pathology, clinical presentation and outcomes.6 LGSOC is primarily driven by the RAS pathway, which is a key regulator of several aspects of normal cell growth and malignant transformation, and present in a third of all cancers, including LGSOC.1,7 LGSOC is a serious ...